References
- Duffy MJ. The urokinase plasminogen system: role in malignancy. Curr Pharm Design 2004;10:39–49.
- Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Met Rev 2003;22:205–22.
- Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signalling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000;12:613–20.
- Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogen 1999;3:15–23.
- Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Envolving role of uPA/uPAR system in human cancers. Cancer Treat Res 2008;34:122–36.
- Binder BR, Mihaly J. The plasminogen activator inhibitor “paradox” in cancer. Immun Lett 2008;118:116–124.
- Ke SH, Coombs GS, Tachias K, Corey DR, Madison EL. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 1997;272:20456–62.
- Rockway TW, Nienaber V, Giranda VL. Inhibitors of protease domain of urokinase-type plasminogen activator. Curr Pharm Design 2002;8:2541–58.
- Rockway TW, Giranda VL. Inhibitors of the proteolytic activity of urokinase type plasminogen activator. Curr Pharm Design 2003;9:1483–98.
- Spraggon G, Philips C, Nowak UK, Ponting CP, Saunders D. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 2000;8:681–91.
- Nienaber VL, Davidson D, Edalji R, Giranda VL, Klinghofer V, Henkin J. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Struct Fold Des 2000;8:553–63.
- Katz BA, Mackman R, Luong C, Radika K, Martelli A, Sprengeler PA, et al. Structural basis for selectivity of small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol 2000;7:299–312.
- Schweinitz A, Steimetzer T, Banke IJ, Arlt MJE, Stürzebecher A, Schuster O, et al. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004;279:33613–22.
- Zeslawska E, Schweinitz A, Karcher A, Sondermann P, Sperl S, Stürzebecher J, et al. Crystals of urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. Mol Biol 2000;301:465–75.
- Zeslawska E, Jacob U, Schweinitz A, Coombs G, Bode W, Madison EJ. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors. Mol Biol 2003;328:109–18.
- Tamura S, Weinhouse MI, Roberts CA, Goldman EA, Masukawa K, Anderson SM, et al. Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Biorg Med Chem Lett 2000;10:983–7.
- Markowska A, Bruzgo I, Midura-Nowaczek K. Effects of tripeptides on the amidolytic activities of urokinase, thrombin, plasmin and trypsin. Int J Pept Res Ther 2008;14:215–18.
- Okada Y, Tsuda Y, Teno N, Wanaka K, Bohgaki M, Hijikata-Okunomiya A, et al. Synthesis of active center-directed peptide inhibitors of plasmin. Chem Pharm Bull 1988;36:1289–97.
- Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22:3099–108.
- Markowska A, Bruzgo I, Midura-Nowaczek K. Low molecular peptides as potential inhibitors of plasmin. Acta Pol Pharm 2007;64:355–8.
- Midura-Nowaczek K, Lepietuszko I, Bruzgo I. Synthesis of alkylamides of dipeptides as potential plasmin inhibitors. Acta Pol Pharm 2006;63:33–7.
- Hervio LS, Coombs GS, Bergstrom RC, Trivedi K, Corey DR, Madison EL. Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates. Chem Biol 2000;7:443–53.